Results 51 to 60 of about 6,419 (213)

Severe COVID-19 caused by persistent SARS-CoV-2 infection successfully treated with dual direct acting antivirals [PDF]

, 2022
We report the use of combination therapy with remdesivir and nirmatrelvir/ritonavir (Paxlovid) in successfully treating severe, chronic COVID-19 caused by persistent SARS-CoV-2 infection over 4 months.
Snell, Luke Blagdon, Bakrania, Prijay, Williams, Tom G.S., Tam, Jerry, Da Silva Fontoura, Dayana, Shaw, Emily, Daunt, Anna, Edgeworth, Jonathan, Hemsley, Carolyn J., Fields, Paul, Agarwal, Sangita, Lams, Boris, Cahill, Helen, Milligan, Iain, Botgros, Alina, Nebbia, Gaia, Douthwaite, Sam, Aarons, Emma J.   +17 more
core  

RECOVER Query: Paxlovid

, 2022
The overall goals of this query are to 1) characterize the growth in patients receiving Paxlovid over time and 2) examine Paxlovid use by patient characteristics, including by acute SARS CoV-2 infection profile and healthcare utilization. Patients with a COVID index date or a visit date between 12/1/2021 (7 days before EUA) and 5/30/2022 are included ...
openaire   +1 more source

Paxlovid™ reduces the incidence of pneumonia, hospitalization, and death in a cohort of COVID-19 patients from northeast Mexico

Journal of Infection and Public Health
Background: Information on Paxlovid™ effectiveness must be monitored and updated in real world scenarios. Our research question was what is the effectiveness of Paxlovid™ in adult patients with COVID-19?
María Elena Camacho Moll, Ana Maria Salinas Martínez, Minna Wu, Gloria Navarrete Floriano, Juan Carlos Romo Salazar, Jorge Eleazar Cruz Luna, Mario Bermúdez de León   +6 more
doaj   +1 more source

A case report of severe hyponatremia secondary to Paxlovid‐induced SIADH

Clinical Case Reports, 2023
Key Clinical Message Nirmatrelvir‐ritonavir (Paxlovid) is a brand‐new oral antiviral medication for treating mild to severe COVID‐19. The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for ritonavir‐nirmatrelvir on ...
Sarah Mohamed, Mostafa Reda Mostafa, Mohamed Magdi Eid, Yossef Hassan AbdelQadir, Yomna Ali Abdelghafar, Sarya Swed, Bishara Jahshan, Waddah Abd El‐Radi   +7 more
doaj   +1 more source

Projected COVID-19 Mortality Reduction From Paxlovid Rollout

JAMA Health Forum, 2023
This decision analytical model study assesses projections of simulated effects of Paxlovid rollout on hospitalizations and mortality using 10 models.
Khunte, Mihir, Kumar, Soryan, Salomon, Joshua A., Bilinski, Alyssa   +3 more
openaire   +2 more sources

SARS-CoV-2 Proteases: Role and Potential as Drug Target [PDF]

, 2023
The coronavirus disease of 2019 (COVID-19) has become a long global pandemic caused by a transmitted and pathogenic virus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Sudiro, Tjahjani Mirawati, Swestikaputri, Chrecentia Hanna   +1 more
core   +2 more sources

Sphinganine‐phosphate prevents influenza infection via promoting CD8+ T cells proliferation and activation

VIEW, EarlyView.
This study established clinical cohorts of respiratory viral infections and identified sphinganine‐phosphate (SA) as a metabolite significantly upregulated post‐infection through metabolomic analysis. In vitro and in vivo experiments demonstrated that SA promotes the generation of effector CD8+ T cells via the SOCS1/JAK1/STAT1 pathway, which ...
Zhongwen Hu, Guiling Yan, Junhong Li, Yuan Yuan, Hong Zhang, Yuchao Zhong, Yuanyuan Peng, Wenjia Zhang, Xiaoyan Su, Changchun Niu, Yang Luo   +10 more
wiley   +1 more source

Situation Analysis of Pharmacovigilance to Medicines in the Western Pacific Region [PDF]

, 2023
聖路加国際大学修士(公衆衛生学 ...
Hitomi, Kubota, 久保田, 瞳
core  

Inhibitors Targeting SARS‐CoV‐2 Papain‐Like Protease: Screening, Design, Synthesis, and Biological Evaluation

ChemMedChem, Volume 21, Issue 9, 14 May 2026.
In our study, we obtained both non‐covalent and covalent PLpro inhibitors. Additionally, the stable protein‐ligand interactions of the active compound were examined using advanced computational docking and molecular dynamics simulations. The non‐covalent inhibitor 2t showed antiviral activity with an EC50 of 2.89 µM, indicating its potential as a ...
Elena‐Oriana Iuga, Nilu Gone, Mariana Ortiz de Godoy, Gabriel Correa Verissimo, Giovanna de Jesus Agostinetto, Liam Urich, Nadine Krüger, Thales Kronenberger, Rafael Victorio Carvalho Guido, Anthony J. O’Donoghue, Stefan A. Laufer, Thanigaimalai Pillaiyar   +11 more
wiley   +1 more source

Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review

Advances in Respiratory Medicine
Nirmatrelvir/Ritonavir is an oral treatment for mild to moderate COVID-19 cases with a high risk for a severe course of the disease. For this paper, a comprehensive literature review was performed, leading to a summary of currently available data on ...
Sydney Paltra, Tim O. F. Conrad
doaj   +1 more source